Long-term cervical cancer prevention strategies across the globe

Gynecologic Oncology

Volumn 117, Issue 2 SUPPL., 2010, Pages

  Cuzick, Jack ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cervical cancer; Cytology; HPV DNA test; HPV vaccine; Long term data

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADENOCARCINOMA; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CYTOLOGY; DNA DETERMINATION; DRUG EFFICACY; HEALTH PROGRAM; HUMAN; LONG TERM CARE; PRACTICE GUIDELINE; PRECANCER; PRIORITY JOURNAL; REVIEW; SCREENING TEST; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VAGINA CANCER; VULVA CANCER; WART VIRUS;

ADOLESCENT; ADULT; FEMALE; HUMANS; LONGITUDINAL STUDIES; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 77949492045     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2010.01.025     Document Type: Review

References (32)

1. Cuzick J., Arbyn M., Sankaranarayanan R., Tsu V., Ronco G., Mayrand M.H., et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 26 Suppl. 10 (2008) K29-K41
2. Franco E.L., and Cuzick J. Cervical cancer screening following prophylactic human papillomavirus vaccination. Vaccine 26 Suppl 1 (2008) A16-A23
3. Anttilaa A., and Ronco G. Description of the national situation of cervical cancer screening in the member states of the European Union. Eur. J. Cancer 45 (2009) 2685-2708
4. Wright Jr. T.C., Schiffman M., Solomon D., Cox J.T., Garcia F., Goldie S., et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet. Gynecol. 103 (2004) 304-309
5. Ronco G., Giorgi-Rossi P., Carozzi F., Confortini M., Dalla Palma P., Del Mistro A., et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J. Natl. Cancer Inst. 100 (2008) 492-501
6. Castle P.E., Fetterman B., Poitras N., Lorey T., Shaber R., and Kinney W. Five-year experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet. Gynecol. 113 (2009) 595-600
7. Cuzick J., Clavel C., Petry K.U., Meijer C.J., Hoyer H., Ratnam S., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 119 (2006) 1095-1101
8. Giorgi-Rossi P., Segnan N., Zappa M., Naldoni C., Zorzi M., Confortini M., et al. The impact of new technologies in cervical cancer screening: results of the recruitment phase of a large randomised controlled trial from a public health perspective. Int. J. Cancer 121 (2007) 2729-2734
9. Mayrand M.H., Duarte-Franco E., Rodrigues I., Walter S.D., Hanley J., Ferenczy A., et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med. 357 (2007) 1579-1588
10. Leinonen M., Nieminen P., Kotaniemi-Talonen L., Malila N., Tarkkanen J., Laurila P., et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J. Natl. Cancer Inst. 101 (2009) 1612-1623
11. Cuzick J., Szarewski A., Mesher D., Cadman L., Austin J., Perryman K., et al. Long-term follow-up of cervical abnormalities among women screened by HPV testing and cytology-results from the Hammersmith study. Int. J. Cancer 122 (2008) 2294-2300
12. Dillner J., Rebolj M., Birembaut P., Petry K.U., Szarewski A., Munk C., et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 337 (2008) a1754
13. Bulk S., Bulkmans N.W., Berkhof J., Rozendaal L., Boeke A.J., Verheijen R.H., et al. Risk of high-grade cervical intra-epithelial neoplasia based on cytology and high-risk HPV testing at baseline and at 6-months. Int. J. Cancer 121 (2007) 361-367
14. Szarewski A., Cadman L., Mallett S., Austin J., Londesborough P., Waller J., et al. Human papillomavirus testing by self-sampling: assessment of accuracy in an unsupervised clinical setting. J. Med. Screen. 14 (2007) 34-42
15. Denny L., Kuhn L., Pollack A., and Wright Jr. T.C. Direct visual inspection for cervical cancer screening: an analysis of factors influencing test performance. Cancer 94 (2002) 1699-1707
16. Denny L., Kuhn L., Pollack A., Wainwright H., and Wright Jr. T.C. Evaluation of alternative methods of cervical cancer screening for resource-poor settings. Cancer 89 (2000) 826-833
17. Sarian L.O., Derchain S.F., Naud P., Roteli-Martins C., Longatto-Filho A., Tatti S., et al. Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin AMerican Screening) study. J. Med. Screen. 12 (2005) 142-149
18. Dunne E.F., Datta S.D., and Markowitz L. A review of prophylactic human papillomavirus vaccines: recommendations and monitoring in the US. Cancer 113 10 Suppl. (2008) 2995-3003
19. Fairley C, Hocking J, Chen M, Donovan B, Bradshaw C. Rapid decline in warts after national quadrivalent HPV vaccine program. Presented at the 25th International Papillomavirus Conference: Clinical & Educational Workshop; 2009 May 8-14; Malmö, Sweden. Abstract O-29.02.
20. "Department of Health. Further guidance on the implementation of the HPV vaccination catch-up campaign.' Gateway reference no. 11185. London: Department of Health; 2009. Available from: http://www.immunisation.nhs.uk/Publications/DS_HPV_letter_30Jan09.pdf.
21. Cuzick J, Castañón A, Sasieni P. Predicted impact of vaccination against human papillomavirus 16/18 on cancer incidence and cervical abnormalities in women aged 20-29 in England. Br J Cancer. In press.
22. Paavonen J., Naud P., Salmerón J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374 (2009) 301-314
23. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
24. GlaxoSmithKline Vaccine HPV-007 Study Group. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 374 (2009) 1975-1985
25. Wheeler C, Teixeira J, Romanowski B, De Carvalho N, Dubin G, Schuind Al. High and sustained HPV 16 and 18 antibody levels through 6.4 years in women vaccinated with Cervarix™ (GSK HPV-16/18 ASO4 vaccine). Presented at the 26th Annual meeting of the European Society for Paediatric Infectious Diseases; 2008 May 13-17; Graz, Austria.
26. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N. Engl. J. Med. 356 (2007) 1915-1927
27. Ault KA; Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369 (2007) 1861-1868
28. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br. J. Cancer 95 (2006) 1459-1466
29. Rowhani-Rahbar A, Mao C, Alvarez FB, Bryan JT, Hawes SE, Hughes JP, et al. Long-term efficacy of a prophylactic human papillomavirus type 16 vaccine. Presented at the 25th International Papillomavirus Conference: Clinical & Educational Workshop; 2009 May 8-14; Malmö, Sweden. Abstract O-01.03.
30. de Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., and zur Hausen H. Classification of papillomaviruses. Virology 324 (2004) 17-27
31. Brown D; Future Study Group. Presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2007 Sept 17-20; Chicago, Illinois.
32. Joura E.A., Leodolter S., Hernandez-Avila M., Wheeler C.M., Perez G., Koutsky L.A., et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369 (2007) 1693-1702